233
Views
0
CrossRef citations to date
0
Altmetric
REVIEW

Characterization of Drug with Good Glass-Forming Ability Loaded Mesoporous Silica Nanoparticles and Its Impact Toward in vitro and in vivo Studies

, , , , & ORCID Icon
Pages 2199-2225 | Received 07 Dec 2023, Accepted 18 Feb 2024, Published online: 05 Mar 2024
 

Abstract

Solid oral dosage forms are mostly preferred in pharmaceutical formulation development due to patient convenience, ease of product handling, high throughput, low manufacturing costs, with good physical and chemical stability. However, 70% of drug candidates have poor water solubility leading to compromised bioavailability. This phenomenon occurs because drug molecules are often absorbed after dissolving in gastrointestinal fluid. To address this limitation, delivery systems designed to improve the pharmacokinetics of drug molecules are needed to allow controlled release and target-specific delivery. Among various strategies, amorphous formulations show significantly high potential, particularly for molecules with solubility-limited dissolution rates. The ease of drug molecules to amorphized is known as their glass-forming ability (GFA). Specifically, drug molecules categorized into class III based on the Taylor classification have a low recrystallization tendency and high GFA after cooling, with substantial “glass stability” when heated. In the last decades, the application of mesoporous silica nanoparticles (MSNs) as drug delivery systems (DDS) has gained significant attention in various investigations and the pharmaceutical industry. This is attributed to the unique physicochemical properties of MSNs, including high loading capacity, recrystallization inhibition, excellent biocompatibility, and easy functionalization. Therefore, this study aimed to discuss the current state of good glass former drug loaded mesoporous silica and shows its impact on the pharmaceutical properties including dissolution and physical stability, along with in vivo study. The results show the importance of determining whether mesoporous structures are needed in amorphous formulations to improve the pharmaceutical properties of drug with a favorable GFA.

Graphical Abstract

Acknowledgments

We would like to thank the National Research and Innovation Agency (BRIN, RIIM3) and the Indonesia Endowment Funds for Education (LPDP) for supporting this work. We also would like to thank Universitas Padjadjaran for APC.

Disclosure

The authors report no conflicts of interest in this work.

Additional information

Funding

This research was funded by the National Research and Innovation Agency (BRIN, RIIM3) and the Indonesia Endowment Funds for Education (LPDP) to Diah Lia Aulifa (No.: 61/IV/KS/5/2023; No.: 2131/UN6.3.1/PT.00/2023).